A carregar...
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National...
Na minha lista:
| Publicado no: | Future Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036749/ https://ncbi.nlm.nih.gov/pubmed/31746224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0042 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|